IR Portal for NeuroSearch
OMX Copenhagen: NEUR.CO
Seneste Kurs: 7,60
-10,59
Branche: Sundhed
RESSOURCER
28/2 2012Presentation 2011 report
17/11 2011Q3 2011 presentation
27/9 2011 Huntexil Phase 3 and restructuring
17/11 2011Q3 2011 presentation
27/9 2011 Huntexil Phase 3 and restructuring
Senest opdateret 28/2 2012
VIRKSOMHEDSBESKRIVELSE:
About NeuroSearch A/S
NeuroSearch A/S is a European based biopharmaceutical company, specialising in CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a pipeline of speciality CNS drugs, including Huntexil® (pridopidine), a unique orphan drug in Phase III for the treatment of Huntington’s disease. NeuroSearch is building commercial competences with a view to commercialising Huntexil® through an in-house marketing and sales organisation.
NeuroSearch has a well-established drug discovery division, NsDiscovery, with unique capabilities in the field of ion channels and CNS diseases. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. NeuroSearch also has equity interests in a number of unlisted companies in the Life Science industry.
NeuroSearch A/S is a European based biopharmaceutical company, specialising in CNS diseases, and listed on NASDAQ OMX Copenhagen A/S (NEUR). The company has a pipeline of speciality CNS drugs, including Huntexil® (pridopidine), a unique orphan drug in Phase III for the treatment of Huntington’s disease. NeuroSearch is building commercial competences with a view to commercialising Huntexil® through an in-house marketing and sales organisation.
NeuroSearch has a well-established drug discovery division, NsDiscovery, with unique capabilities in the field of ion channels and CNS diseases. The company has strategic drug discovery and development alliances with Janssen Pharmaceutica and Eli Lilly as well as a licence collaboration with Abbott. NeuroSearch also has equity interests in a number of unlisted companies in the Life Science industry.
INVESTOR RELATIONS KONTAKT
Executive Vice President & CFO, Corporate Finance, Legal & Investor Relations
e-mail:
Senest opdateret 11/3 2011
FINANSIELLE TAL
| DKK’000 | 2011 | 2010 | 2009 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 84.579 |
| Research and development costs | 259.133 | 144.403 | 401.677 |
| Administrative expenses | 123.409 | 23.307 | 38.712 |
| Operating profit (EBIT) | -382.542 | 167.610 | -355.810 |
| Profit/(loss) of continuing operations before tax | -349.079 | -145.816 | 24.608 |
| Net profit/(loss) of discontinued operations | -329.339 | -160.430 | 44.064 |
| Net profit/loss for the year | -678.418 | -259.002 | -287.138 |
| Capital resources ultimo | 220.640 | 480.600 | 967.612 |
| Total assets | 840.816 | 1.391.530 | 1.630.043 |
| Total equity | 320.632 | 994.067 | 1.173.827 |
| Total number of shares in thousands | 24.554 | 24.554 | 24.380 |
| EPS | -27,63 | -10,55 | -11,78 |
| BVPS | 13,06 | 40,50 | 48,10 |
| Average number of employees | 222 | 235 | 235 |
Senest opdateret 29/2 2012
Operating loss on continuing operations of approximately DKK 75 million excluding any possible costs related to the phase III programme on Huntexil
Forventet: 2012
Forventet: 2012
The Prime-HD study will not be initiated before financing is secured to finalise the study. So far, no decision on preferred route of financing has been taken
Forventet: 2012
Forventet: 2012
No further costs related to the discontinued operations are expected in 2012. The cash flow effect in 2012 is expected to be in the region of DKK 70 million
Forventet: 2012
Forventet: 2012
Huntexil: Final results from the Multiple Ascending Dose study during Q2 2012
Forventet: 2012
Forventet: 2012
Senest opdateret 28/2 2012
Nordea Bank Danmark A/S
Michael Novod
Michael Novod
ABG Sundal Collier ASA
Peter Hugreffe Ankersen
Peter Hugreffe Ankersen
Carnegie Bank A/S
Carsten Lønborg Madsen
Carsten Lønborg Madsen
Senest opdateret 25/1 2011
Patrik Dahlen
CEO
Finn Eggert Sørensen
Executive Vice President, CBO
Karin Garre
Executive Vice President, Drug Development & CMO
René Schneider
Executive Vice President & CFO, Corporate Finance, Legal & Investor Relations
Senest opdateret 11/3 2011
BEGIVENHEDER
Senest opdateret 25/5 2012
Senest opdateret 9/5 2012
Aktiekurs for NeuroSearch
Du skal opdatere din Flash Player for at se dette indhold
DINE MULIGHEDER
| Dit kursmål: ingen |
| Gennemsnitligt kursmål (AVG): 0,00 (0) |
| Hvor vil NeuroSearch lukke fra deres nuværende pris? Over  eller under  den nuværende kurs? |
|||
| Om en måned |
Om tre måneder |
Om seks måneder |
Om et år |
|
Brugernes anbefaling
SALG
KØB
|
|||
SKRIV INDLÆG
saving..
;){kind=link}